European Pharmacopoeia -ph. Eur.- Monograph Tablets -0478- [upd] < 2026 Update >

: Since January 2018, revised standards mandate a suitable dissolution test for immediate-release forms unless otherwise justified.

If you are developing a specific tablet formulation or preparing a regulatory dossier, let me know:

To reflect the diversity of modern pharmaceutical formulations, monograph 0478 distinguishes several categories of tablets, each with its own specific considerations: European Pharmacopoeia -ph. Eur.- Monograph Tablets -0478-

: They are primarily obtained by compressing uniform volumes of particles or particle aggregates, but can also be produced via extrusion, molding, or freeze-drying (lyophilization).

The monograph outlines several "mandatory" tests that tablets must pass to be compliant. These include: Uniformity of Dosage Units : Since January 2018, revised standards mandate a

(disintegrating in the mouth within 3 minutes). Key Quality Control Requirements

The heart of Monograph 0478 lies in its mandated quality control tests. These tests are designed to guarantee that every batch of tablets meets predefined criteria for identity, purity, and performance. These include: Uniformity of Dosage Units (disintegrating in

The monograph mandates essential quality tests to ensure safety, efficacy, and consistent manufacturing.

The monograph excludes certain specialized forms from its direct requirements: .